In summary, several products are being developed to address the significant unmet needs that exist in the schizophrenia marketplace. For example, three potential treatments—ITI-007 (Intra-Cellular Therapies), MIN-101 (Minerva Neurosciences), and NaBen (SyneuRx)—are aimed at managing the negative symptoms of the disease. In addition, AVN-211 (Avineuro Pharmaceuticals) is in late-stage development as a treatment for the cognition impairments associated with schizophrenia, and Lu AF35700 (Lundbeck) addresses treatment resistance in schizophrenia patients. Finally, three formulations of risperidone—risperidone implant (Braeburn Pharmaceuticals), risperidone ISM (Rovi), and RBP-7000 (Indivior)—are expected to offer improved safety profiles.6
7 Likes
thank you for posting @everhopeful !
1 Like
wtf is nimh doing anyways? These arent theyre products. I am glad in 7 years BRAIN initiative will be done, hopefully its useful.
2 Likes